laitimes

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

Recently, dozens of national respiratory leaders and well-known experts gathered in the cloud to focus on the research progress of asthma diagnosis and treatment in China, help achieve accurate identification of asthma, create a new era of respiratory diagnosis, and jointly witness the release of China's first stimulator approved for bronchocystimation test. The National Cloud Listing Conference for Clinical Acetylcholine hosted by Chia Tai Tianqing was successfully held.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

The listing of Tianqing Express has truly solved the problem of clinical airway excitation test excitators, enabling China to officially carry out standardized airway excitation tests with acetyl methacholine as the excitator, which is of great significance for the diagnosis and treatment of respiratory diseases

This conference is very honored to invite Academician Wang Chen, Vice President of the Chinese Academy of Engineering, President of the Chinese Academy of Medical Sciences, and President of Peking Union Medical College, to serve as honorary chairman, and Academician Wang Chen congratulated and delivered a speech online. He said that in recent years, the clinical use of acetylmecholine has attracted much attention in the Chinese respiratory community, and experts are looking forward to the emergence of in vivo diagnostic drugs that meet the regulations and reach the quality of clinical use. The listing of Tianqing Express has truly solved the problem of clinical airway excitation test excitators, enabling China to officially carry out standardized airway excitation tests with acetyl methacholine as the excitator, which is of great significance for the diagnosis and treatment of respiratory diseases.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

In the connection link between the three venues of the conference, Yu Kangxin, president of Chia Tai Tianqing Pharmaceutical Group Co., Ltd., delivered a speech, saying that Chia Tai Tianqing has been grinding a sword for six years, successfully developing and listing acetylmedcholine, filling the gap of the domestic bronchial excitation test excitator, which will help the bronchial excitation test to be carried out in China and promote asthma prevention and control work to a new level.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

The conference was co-chaired by Professor Shen Huahao of the Second Affiliated Hospital of Zhejiang University School of Medicine, Professor Zheng Jinping of the First Affiliated Hospital of Guangzhou Medical University, Professor Sun Yongchang of the Third Hospital of Peking University, Professor Song Yuanlin of Zhongshan Hospital Affiliated to Fudan University, and Professor Song Yong of Jinling Hospital Affiliated to Nanjing University School of Medicine.

Professor Shen Huahao said that the listing of Tianqing Express Letter has made colleagues in the field of asthma and lung function rejoice, and in the future, it is expected that Tianqing Express Letter can play a greater role in the early detection of mild asthma and the over-diagnosis of asthma and COPD.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

Professor Zheng Jinping believes that lung function tests are extremely important in assessing the severity of the disease, the diagnosis and efficacy of the disease. The marketing of clinical methacholine provides a favorable weapon for the evaluation of airway reactions in asthma and other allergic diseases.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

Professor Sun Yongchang said that the CPH study (China Lung Health Research) led by Academician Wang showed that there are more than 47 million asthma patients in people over 20 years old, and more than 70% of patients have not been diagnosed. Therefore, the improvement of diagnostic technology and the standardization of early diagnosis, treatment and management of chronic respiratory diseases require the joint efforts of experts to improve the level of prevention and treatment of chronic respiratory diseases.

Professor Song Yuanlin expressed the hope that under the joint promotion of the pulmonary function group, the asthma group and the COPD group, the standardized diagnosis and treatment of chronic airway diseases and the promotion and standardization of provocative tests can make great progress.

Professor Song Yong mentioned that Chia Tai Tianqing has made great contributions to the diagnosis and treatment of respiratory diseases in China, and Tianqing's efforts deserve our praise, and we look forward to the widespread application of Tianqing Express after its listing.

Bronchial provocation test is the most commonly used and accurate clinical examination to detect airway hyperreactivity, and is an important indicator of asthma diagnosis

In the session chaired by Professor Song Yuanlin of Zhongshan Hospital affiliated to Fudan University, Dong Ping, director of Chia Tai Tianqing Pharmaceutical Group Research Institute, made an academic report on the research and development process of acetyl methacholine for clinical use. He pointed out that in the past six years, Chia Tai Tianqing has devoted himself to research, broken through technical barriers, and realized the localization of acetylmecholine production. Tianqing Express Letter is the first stimulator of the bronchial excitation test in China, developed according to high standards and consistent with the quality of the original research. In 2022, Chia Tai Tianqing will officially expand from therapeutic drugs to diagnostic drugs, realize the integration of diagnosis and treatment, accurately identify, lead the norms, and create a new era of respiratory diagnosis.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

Subsequently, Professor Zheng Jinping of the First Affiliated Hospital of Guangzhou Medical University made a special report on "Clinical Application of Bronchial Provocation Test". He said that the occurrence of airway inflammation, neurological factors, changes in the osmolality of the airway surface and other factors are related to the occurrence of airway hyperreactivity. AHR is one of the most dominant features of bronchial asthma and is an indirect reflection of airway inflammation. Bronchial provocation test is the most commonly used and accurate clinical examination to detect airway hyperreactivity, and is an important indicator of asthma diagnosis. With the listing of Chia Tai Tianqing's Tianqing Express, China has realized the localization production of acetyl methacholine, filling the clinical gap in the standardized diagnosis and treatment of asthma. Looking back on the past bumpy dispute experience, let us realize that safety norms are more important than waste!

In the high-end dialogue session, Professor Song Yuanlin, Professor Huang Kewu of Beijing Chaoyang Hospital Affiliated to Capital Medical University, Professor Yang Lan of the First Affiliated Hospital of Xi'an Jiaotong University, Professor Lai Guoxiang of the Second People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Professor Zhang Wei of the First Affiliated Hospital of Nanchang University, and Professor Qu Yiqing of Qilu Hospital of Shandong University pointed out that acetyl methacholine, as the first excitator approved for bronchial excitation test in China, solves technical problems such as impurities and moisture absorption, and can not only identify bronchial asthma patients early. It can also distinguish between chronic cough and chronic airway diseases, so that asthma patients can get early treatment, which is of great significance for the diagnosis and standardized management of respiratory diseases.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

The topic discussion session was presided over by Professor Zheng Jinping, Professor Lai Kefang of the First Affiliated Hospital of Guangzhou Medical University, Professor Liu Huiguo of Tongji Hospital Affiliated to Huazhong University of Science and Technology, Professor Liang Zongan of West China Hospital of Sichuan University, Professor Zhang Xiaoju of Henan Provincial People's Hospital, Professor Song Yong, and Professor Xia Jingen of China-Japan Friendship Hospital said that the current difficulty in the standardized diagnosis and treatment of asthma in China lies in the diagnosis of atypical asthma, mild asthma, asthma COPD overlap syndrome and other patients. The approval of Chia Tai Tianqing for official marketing of methanololline will solve these problems.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

At the end of the meeting, Professor Shen Huahao and Professor Zheng Jinping pointed out in their concluding speeches that the acetyl methacholine developed by Chia Tai Tianqing can improve the accuracy of asthma diagnosis and achieve early diagnosis and early treatment of various types of asthma. In the future, experts will need to work together to benefit more patients with chronic respiratory diseases and achieve the goal of "zero deaths from asthma".

Academic thematic discussions were held at the three venues to discuss the methods and quality control of bronchial provocation tests

At the Beijing-Tianjin-Hebei venue, chaired by Professor Huang Kewu and professor Chen Yahong of the Third Hospital of Peking University, in the academic report, he explained the methods and quality control of bronchial provocation test, and introduced the importance, indications and contraindications of bronchial provocation test, and pointed out that bronchial provocation test is a necessary condition for discipline construction.

Subsequently, Professor Liu Changshan of the Second Hospital of Tianjin Medical University, Professor Liu Xiaofang of Beijing Tongren Hospital Affiliated to Capital Medical University, Professor Nie Xiuhong of Xuanwu Hospital of Capital Medical University, and Professor Zhang Jie of Beijing Tiantan Hospital Affiliated to Capital Medical University said in the high-end dialogue session that the listing of Tianqing Express has brought good news to patients with asthma and high airway response.

In the topic discussion session, under the auspices of Professor Liu Chuanhe of the Children's Hospital Affiliated to the Capital Institute of Pediatrics, Professor Mou Xiangdong of Beijing Tsinghua Changgeng Hospital, Professor Xiang Pingchao of Peking University Shougang Hospital, Professor Zhu Guangfa of Beijing Anzhen Hospital affiliated to Capital Medical University, and Professor Zhang Zhongping of Hebei Children's Hospital believe that bronchial stimulation tests should first take safety precautions, and when choosing the location of the lung function room, they should take into account the problem of patient rescue, equipped with necessary devices, drugs and emergency plans. Second, follow the guidelines for medication, observe the changes in patient indicators, and when the patient leaves, FEV1 should return to normal to ensure patient safety.

Subsequently, under the presidency of Professor Xu Baoping of Beijing Children's Hospital affiliated to Capital Medical University, Professor Chen Liang of Beijing Jingmei Group General Hospital, Professor Wang Jinxiang of Beijing Luhe Hospital affiliated to Capital Medical University, Professor Yan Li of Hebei Provincial People's Hospital, and Professor Zhou Yunzhi of Emergency General Hospital pointed out that Chia Tai Tianqing needs to further carry out promotion work to let more doctors understand the stimulation test, and at the same time, medical insurance, pharmacy department and other departments need to strengthen support in order to benefit patients faster.

At the end of the meeting, Professor Huang Kewu and Professor Sun Yongchang made concluding remarks on the meeting, expressing the hope that the specifications of Tianqing Express can be more convenient and easy to use, and in terms of pricing, they also hope to get government support to better serve patients.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

At the Yangtze River Delta venue, Professor Song Yong of Jinling Hospital Affiliated to Nanjing University School of Medicine presided over the meeting, and Professor Zhang Min of the First People's Hospital Affiliated to Shanghai Jiao Tong University brought a special report entitled "Methods and Quality Control of Bronchial Excitation Test".

Subsequently, Professor Li Wen of the Second Affiliated Hospital of Zhejiang University School of Medicine, Professor Sun Gengyun of the First Affiliated Hospital of Anhui Medical University, Professor Xie Baosong of Fujian Provincial Hospital, and Professor Zhao Deyu of the Children's Hospital Affiliated to Nanjing Medical University pointed out that to screen patients who can carry out bronchectation tests, it is first necessary to clarify the patient's medical history, and secondly, to be equipped with certain emergency measures. It is safer to have a bronchial provocative test in children >70% of children over 6 years of age and fev1 and wait for lung function to return to normal before leaving.

In the topic discussion session, under the auspices of Professor Song Yuanlin, Professor Jin Meiling of Zhongshan Hospital affiliated to Fudan University, Professor Liang Binmiao of West China Hospital of Sichuan University, Professor Sun Peili of Jiangsu Provincial People's Hospital, Professor Zhao Guihua of Henan Provincial People's Hospital, and Professor Gu Wei of Nanjing First Hospital believe that bronchial excitation tests are generally safer, but in order to avoid risks, emergency plans should be prepared. First of all, we must grasp the indications and contraindications, followed by the participation of experienced doctors, and finally the scene should be equipped with rescue facilities.

Subsequently, under the auspices of Professor Yao Xin of Jiangsu Provincial People's Hospital, Professor Lin Yong of Nanjing Chest Hospital of Southeast University School of Medicine, Professor Xiao Yonglong of Gulou Hospital Affiliated to Nanjing University School of Medicine, Professor Zhang Ruifeng of Zhongda Hospital Affiliated to Southeast University, Professor Feng Jian of Affiliated Hospital of Nantong University, and Professor Chen Bi of Affiliated Hospital of Xuzhou Medical University said that it is recommended to formulate standardized SOPs, train and assess lung function rooms and clinicians, and only after passing the assessment can bronchial challenge tests be carried out.

At the end of the meeting, Professor Song Yuanlin and Professor Huang Mao of Jiangsu Provincial People's Hospital pointed out that the operation of standardized bronchial stimulation test is the top priority, and the doctors who carry out the trial need to have corresponding qualification requirements.

At the Pearl River Delta venue, chaired by Professor Zheng Jinping and professor Gao Yi of the First Affiliated Hospital of Guangzhou Medical University, he stressed in the special report that the bronchial excitation test must be strictly controlled, including atomization equipment, excitation reagent configuration and preservation, subject cooperation, and examination time. Tianqing Express has overcome the technical barriers of research and development, realized the precision of the test process, and brought more benefits to the diagnosis of asthma diagnosis and elimination of asthma.

Subsequently, Professor Guo Yubiao of the First Affiliated Hospital of Sun Yat-sen University, Professor Gao Xinglin of Guangdong Provincial People's Hospital, Professor Chen Xin of Zhujiang Hospital of Southern Medical University, and Professor Li Dongming of the Affiliated Hospital of Guangdong Medical University believe that the listing of acetylmecholine in China will bring benefits to more patients, especially patients with chronic cough in outpatient clinics, and the type of asthma can be determined through bronchial provocation tests.

Topic discussion session, under the auspices of Professor Lai Kefang, Professor Jiang Shanping of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Professor Wu Haihong of Hainan Provincial People's Hospital, Professor Li Minjing of the First People's Hospital of Foshan City, and Professor Zhang Min of the Second People's Hospital of Shenzhen City said that the side reactions of histamine not only make patients hoarse and cough, but also have a great impact on operational technicians.

Subsequently, under the auspices of Professor Cai Shaoxi of the Southern Hospital of Southern Medical University, Professor Zhang Tiantuo of the Third Affiliated Hospital of Sun Yat-sen University, Professor Liu Shengming of the First Affiliated Hospital of Jinan University, Professor Liang Jianping of Zhongshan People's Hospital, and Professor Zhang Ping of Dongguan People's Hospital participated in the discussion, pointing out that the popularization of drugs requires the use of PCCM to go to the grass-roots level to conduct academic exchanges and learn standardized operations.

At the end of the meeting, Professor Lai Kefang pointed out in his speech that the promotion and popularization of bronchial stimulation tests can benefit more patients through standardized training and the power of experts. The listing of acetylmecholine has contributed to the construction of the discipline and clinical diagnosis and treatment to a certain extent.

Accurate identification, leading the norm – China's first approved stimulant for bronchial excitation testing is released on the market

End of this article

Editor-in-Charge: Jerry

Follow us

Read on